CATALYST BIOSCIENCES INC

NASDAQ

CBIO

weekly chart wilder ma

short term target on chart see some MOMO until FDA news coming out 07/18/2018 Phase 2 commencement of Part 2 of Phase 2/3 trial announced January 4, 2018. Interim data due at ISTH July 18, 2018. Final data due at ASH 2018. potential gapper candidate

cbio has been popping up multiple times on my scans playing around in my action zone between the 10ma and 30ema with 5 consecutive down days + nr7 inside day on low volume. Looks to be holding those supports quite well, triangulating and Volume has been drying up nicely. I would normally like to get in just above that inside days high but with current market...

Waiting for a spike to trade if good trial data comes out.

CBIO seems forming a very nice fallen angel formation. It has history of sharp breakout, and at this time it seems getting ready for another breakout. We are looking for a quick day trade if it breaks above $4.70 * Trade Criteria * Date First Found- June 29, 2017 Pattern/Why- Fallen angel formation Entry Target Criteria- Break of $4.70 Exit Target Criteria-...

U.S. Government Required Disclaimer - Commodity Futures Trading Commission Futures, Stocks and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation...

$CBIO Recent Highlights and Upcoming Milestones Recent Highlights: Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis...

expec tlong or bi g gap up

expect long this stock for april, then drop from higher?? might be. anyway i expect a 200% return at least. if more might be my jackpot :D small stop

Why did CBIO stock shares practically triple? On longer charts,stock worth over $3,000 share once. Catalyst Biosciences Inc. (CBIO) saw its shares practically triple in Tuesday’s session after the company announced a critical regulatory approval. The company reported that the Korean Ministry of Food and Drug Safety (MFDS) approved the Investigational New Drug...

A too much great spike history to not repeat.

CBIO, very low float, former runner, better earnings then expected, no real resistance before 10.50$, long there.

Trade playback, 2/3/2017

CBIO long

Reverse Merger took place in September 7/1 Stock Split on 8/25 took Sh.P. from $12-8 Bottomed out 12/18 on HUGE Volume Surge This likely to do with insider purchasing creating a base @ $2.00 Watch a possible bounce 1st breather: $3.09 18.39% Return 2nd breather: $3.39 29.89% Return *See technicals for entry and exit